Emerging Drug Threats Rapid Scheduling Act
A discussion draft that lets DEA control a new synthetic opioid, peptide opioid, or anabolic agent as a class within 15 days instead of one compound at a time — published with its cover memorandum, the adversarial review that tests it, and the citation review of revision 2 that began the revisions.
- Type
- Legislative discussion draft with supporting analysis, prepared for congressional staff review and not for introduction. Drafted as a House vehicle for referral to the Committees on Energy and Commerce and the Judiciary. Not official U.S. government analysis and not the product of the Office of the Legislative Counsel.
- The problem
- Federal law controls new drugs one compound at a time, after they appear, and suppliers change the compound faster than DEA can act. Temporary scheduling under 21 U.S.C. 811(h) needs 30 days’ notice and names individual substances; the Analogue Act does not reach peptides such as dermorphin; a “not for human consumption” label defeats prosecution; and the evidence a scheduling order needs is held by separate agencies.
- What it does
- DEA may control a class, defined by structure or by receptor activity, in 15 days, for three years plus one, with D.C. Circuit review. A new provisional schedule carries Schedule III penalty levels with no mandatory minimums and no possession offense. Dermorphin and other qualifying peptide opioids are controlled on enactment, the labeling defense is closed, and a DEA-led fusion function assembles the evidence. It grants no new collection authority.
- Documents
- LD-2026-03, the cover memorandum; LD-2026-03A, the bill (revision 5); LD-2026-03B, an adversarial review of the revision 5 text; LD-2026-03C, the citation verification and drafting review of revision 2, whose findings were applied in revision 3.
- Open before transmittal
- Dollar placeholders for the marketplace civil penalty and appropriations; the research-reagent quantity limit; forensic-chemist confirmation of the peptide names in Section 7; whether Section 7(a)(11) stays self-executing; whether new 811(k) becomes the exclusive route for class-wide control; whether to keep the exclusion of labeling violations from the felony import offense; re-verification of 21 U.S.C. 802 and 812 and 18 U.S.C. 1961 and 2516 against live Law Revision Counsel text; and three hardening options left open in the adversarial review. A note to committee staff in the bill says who supplies each answer.
- Revision history
- Revision 5, 6 October 2026 — merges two parallel revision 4 drafts. It restores the express Section 230 override and district-court recovery of the marketplace penalty, and carries a third-pass verification that adds the 18 U.S.C. 2516 wiretap amendment, treats provisional substances as Schedule I so the research pathway attaches, and confines the sealed-mail citation to letters of domestic origin, the only mail it protects. Revision 3 had corrected the defects found in the review of revision 2. Published on this site 6 October 2026.
- Class-wide control in 15 days. New 21 U.S.C. 811(k) lets DEA control a class defined by core chemical structure, by functional activity at a specified receptor, or both, on 15 days’ notice, or on publication with a stated finding of imminent hazard.
- A provisional schedule. Interim control sits outside Schedules I–V at Schedule III regulatory and penalty levels, with no medical-use finding required. Before control expires, DEA must start a permanent scheduling proceeding or let it lapse.
- Peptide opioids reached by function. Mu- and delta-opioid agonists are defined by what they do, not what they resemble. Dermorphin and nine named peptides go into Schedule I; endogenous human peptides are excluded.
- The label is no defense. “Not for human consumption” no longer defeats an analogue prosecution, and a jury may infer intent from research chemical marketing, without any shift in the burden of proof. Marketplaces that knowingly facilitate sales face civil penalties recovered in district court, with an express Section 230 override.
- Existing tools, extended. Provisional-schedule substances count as controlled substances for forfeiture, subpoenas, extraterritorial jurisdiction, conspiracy, money laundering and wiretap predicates, through operative amendments to 21 U.S.C. 802(6) and 18 U.S.C. 2516.
- Foreign suppliers through designation, not tariffs. Treasury designation, special measures, the Entity List and prosecution under 21 U.S.C. 959, because Learning Resources v. Trump held that IEEPA does not authorize tariffs.
- Research protected. HALT Fentanyl Act registration procedures apply, provisional substances are treated as Schedule I so those procedures attach, and the 30-day expedited procedure is extended to universities, forensic and public health laboratories, medical examiners and federally funded researchers.
- Checked authority. D.C. Circuit review on substantial evidence, no possession offense, a knowledge element in every prosecution, no new collection authority, GAO and Inspector General review, and a six-year sunset.
The cover memorandum is the leave-behind; the bill is the text; the adversarial review is the argument against it; the citation review is where the revisions began. Start with LD-2026-03 for the problem, what each section does, the safeguards and the legal risk. Read LD-2026-03A for the statutory text and its drafting notes. Read LD-2026-03B for each challenge stated at full strength, with the answer in the draft and the fix where there is none; the two defects it found, Section 230 and SEC v. Jarkesy, are now cured in the bill. LD-2026-03C reviews revision 2; its findings were applied in revision 3, and the current text is revision 5.
The four documents in this series
Each document opens as a PDF in a new tab. Read them in this order.
Related working paper: Declared War on the Cartels, on the U.S. campaign against the fentanyl-producing cartels in Mexico.
What this series does not establish
This is a discussion draft prepared for congressional staff review. It is not a bill introduced in Congress, it is not the product of the Office of the Legislative Counsel, and it is not official U.S. government analysis. Bracketed values are open policy choices, some conforming amendments are left to Legislative Counsel, and the peptide names in Section 7 await confirmation by a forensic chemist. The statutory citations were checked while the Office of the Law Revision Counsel site was under maintenance, and the draft itself asks that they be re-verified against live text before introduction.
The adversarial review states likely outcomes, not predictions of how any court will rule. Pending legislation and agency actions the draft relies on — H.R. 1266, the 7-hydroxymitragynine notice of intent, and the WHO review of medetomidine and etomidate — are stated as of 6 October 2026.
Nothing in this series is legal advice or a substitute for counsel.
Suggested citations
George, Collin B. Emerging Drug Threats Rapid Scheduling Act of 2026. Legislative series LD-2026-03, revision 5. Sanctir LLC, 6 October 2026.
George, Collin B. Emerging Drug Threats Rapid Scheduling Act of 2026: Discussion Draft, Revision 5. Sanctir LD-2026-03A, 6 October 2026.
George, Collin B. Cover Memorandum: Emerging Drug Threats Rapid Scheduling Act of 2026. Sanctir LD-2026-03, 6 October 2026.
George, Collin B. Adversarial Review: Emerging Drug Threats Rapid Scheduling Act of 2026. Sanctir LD-2026-03B, 6 October 2026.
George, Collin B. Emerging Drug Threats Rapid Scheduling Act of 2026: Citation Verification and Drafting Review of Revision 2. Sanctir LD-2026-03C, 6 October 2026.